Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K. Use Of J&J's Cisapride Halted Pending 2001 Ruling On Status In EU

Executive Summary

The U.K.' s Medicines Control Agency is withdrawing Johnson & Johnson's cisapride from the market, pending a decision on the drug's status in the EU, expected in 2001.

You may also be interested in...



Canada Implements New Recall/Disclosure Policy

Health Canada finalizes guideline on its new powers to order recalls or disclose information related to serious risks of injuries for drugs, but says it will develop more details on how it will use the authorities.

J&J Propulsid Compassionate IND Program Expands To Allow Emergency Use

Janssen is adding three IND treatment protocols to its limited access program for Propulsid (cisapride).

J&J Propulsid Compassionate IND Program Expands To Allow Emergency Use

Janssen is adding three IND treatment protocols to its limited access program for Propulsid (cisapride).

Related Content

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel